Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–11. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. doi:10.1016/S0092-8674(00)81683-9.
   PubMed Web of Science ®Google Scholar
• Helmy KY, Patel SA, Nahas GR, Rameshwar P. Cancer immunotherapy: accomplishments to date and future promise. Ther Deliv. 2013;4(10):1307–1320. doi:10.4155/tde.13.88.
   PubMedGoogle Scholar
• Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35(Suppl):S185–s198. doi:10.1016/j.semcancer.2015.03.004.
   PubMed Web of Science ®Google Scholar
• Snell LM, McGaha TL, Brooks DG. Type I interferon in chronic virus infection and cancer. Trends Immunol. 2017;38(8):542–557. doi:10.1016/j.it.2017.05.005.
   PubMed Web of Science ®Google Scholar
• Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, Mathios D, Lim M, Shih I-M, Wang T-L, et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A. 2017;114(51):E10981–e10990 doi: 10.1073/pnas.1712514114.
   PubMed Web of Science ®Google Scholar
• Fuertes MB, Kacha AK, Kline J, Woo S-R, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8(+) T cell responses through CD8α(+) dendritic cells. J Exp Med. 2011;208(10):2005–2016. doi:10.1084/jem.20101159.
   PubMed Web of Science ®Google Scholar
• Fuertes MB, Woo S-R, Burnett B, Fu Y-X, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013;34(2):67–73. doi:10.1016/j.it.2012.10.004.
   PubMed Web of Science ®Google Scholar
• Woo S-R, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015;36(4):250–256. doi:10.1016/j.it.2015.02.003.
   PubMed Web of Science ®Google Scholar
• Breast cancer facts & figures 2017–2018. 2016. [accessed 2019 Nov 1] . www.cancer.org/statistics.
   Google Scholar
• Knutson TP, Lange CA. Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther. 2014;142(1):114–125. doi:10.1016/j.pharmthera.2013.11.010.
   PubMed Web of Science ®Google Scholar
• Grimm SL, Hartig SM, Edwards DP. Progesterone receptor signaling mechanisms. J Mol Biol. 2016;428(19):3831–3849. doi:10.1016/j.jmb.2016.06.020.
   PubMed Web of Science ®Google Scholar
• Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol. 2011;8(11):669–676. doi:10.1038/nrclinonc.2011.110.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448–454. doi:10.1002/ijc.20710.
   PubMed Web of Science ®Google Scholar
• Goodman ML, Trinca GM, Walter KR, Papachristou EK, D’Santos CS, Li T, Liu Q, Lai Z, Chalise P, Madan R, et al. Progesterone receptor attenuates STAT1-mediated IFN signaling in breast cancer. J Immunol. 2019;202(10):3076–3086. doi:10.4049/jimmunol.1801152.
   PubMed Web of Science ®Google Scholar
• Walter KR, Goodman ML, Singhal H, Hall JA, Li T, Holloran SM, Trinca GM, Gibson KA, Jin VX, Greene GL, et al. Interferon-stimulated genes are transcriptionally repressed by PR in breast cancer. Mol Cancer Res. 2017;15(10):1331–1340. doi:10.1158/1541-7786.MCR-17-0180.
   PubMed Web of Science ®Google Scholar
• Fink K, Grandvaux N. STAT2 and IRF9: beyond ISGF3. JAKSTAT. 2013;2:e27521.
   PubMedGoogle Scholar
• Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A. 2004;101(6):1714–1719. doi:10.1073/pnas.0308102100.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Access Network.Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Casella G, Berger RL. Statistical inference. Pacific Grove: CA Duxbury Press; 2001.
   Google Scholar
• Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36–49. doi:10.1038/nri3581.
   PubMed Web of Science ®Google Scholar
• Devasthanam AS. Mechanisms underlying the inhibition of interferon signaling by viruses. Virulence. 2014;5(2):270–277. doi:10.4161/viru.27902.
   PubMed Web of Science ®Google Scholar
• Cottu PH, Bonneterre J, Varga A, Campone M, Leary A, Floquet A, Berton-Rigaud D, Sablin M-P, Lesoin A, Rezai K, et al. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. PLoS One. 2018;13(10):e0204973. doi:10.1371/journal.pone.0204973.
   PubMed Web of Science ®Google Scholar
• Blaszczyk K, Nowicka H, Kostyrko K, Antonczyk A, Wesoly J, Bluyssen HAR. The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 2016;29:71–81. doi:10.1016/j.cytogfr.2016.02.010.
   PubMed Web of Science ®Google Scholar
• Le-Trilling VTK, Wohlgemuth K, Rückborn MU, Jagnjic A, Maaßen F, Timmer L, Katschinski B, Trilling M, et al. STAT2-dependent immune responses ensure host survival despite the presence of a potent viral antagonist. J Virol. 2018;92(14):e00296-18.
   Web of Science ®Google Scholar
• Blaszczyk K, Olejnik A, Nowicka H, Ozgyin L, Chen Y-L, Chmielewski S, Kostyrko K, Wesoly J, Balint B, Lee C-K, et al. STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. Biochem J. 2015;466(3):511–524. doi:10.1042/BJ20140644.
   PubMedGoogle Scholar
• Abdul-Sater AA, Majoros A, Plumlee CR, Perry S, Gu A-D, Lee C, Shresta S, Decker T, Schindler C. Different STAT transcription complexes drive early and delayed responses to type I IFNs. J Immunol. 2015;195(1):210–216. doi:10.4049/jimmunol.1401139.
   PubMed Web of Science ®Google Scholar
• Platanitis E, Demiroz D, Schneller A, Fischer K, Capelle C, Hartl M, Gossenreiter T, Müller M, Novatchkova M, Decker T, et al. A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription. Nat Commun. 2019;10(1):2921. doi:10.1038/s41467-019-10970-y.
   PubMedGoogle Scholar
• Urin V, Shemesh M, Schreiber G. CRISPR/Cas9-based knockout strategy elucidates components essential for type 1 interferon signaling in human HeLa cells. J Mol Biol. 2019;431(17):3324–3338. doi:10.1016/j.jmb.2019.06.007.
   PubMed Web of Science ®Google Scholar
• Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer–An overview and update. Mol Cell Endocrinol. 2015;418(Pt 3(0 3)):220–234. doi:10.1016/j.mce.2015.09.035.
   PubMedGoogle Scholar
• Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018;18(11):1101–1112. doi:10.1080/14737140.2018.1520096.
   PubMed Web of Science ®Google Scholar
• D’Souza A, Spicer D, Lu J. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. J Hematol Oncol. 2018;11(1):80. doi:10.1186/s13045-018-0620-6.
   PubMedGoogle Scholar
• Criscitiello C, Curigliano G. Immunotherapy of breast cancer. Prog Tumor Res. 2015;42:30–43.
   PubMed Web of Science ®Google Scholar
• Yu LY, Tang J, Zhang CM, Zeng WJ, Yan H, Li MP, Chen XP, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health. 2017;14(1).
   Web of Science ®Google Scholar
• Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157. doi:10.1186/s40425-018-0479-7.
   PubMed Web of Science ®Google Scholar
• Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Oncoimmunology. 2018;7(10):e1490854. doi:10.1080/2162402X.2018.1490854.
   PubMed Web of Science ®Google Scholar
• Tolba MF, Omar HA. Immunotherapy, an evolving approach for the management of triple negative breast cancer: converting non-responders to responders. Crit Rev Oncol Hematol. 2018;122:202–207. doi:10.1016/j.critrevonc.2018.01.005.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10):1989–2003. doi:10.1084/jem.20101158.
   PubMed Web of Science ®Google Scholar
• Cheon H, Borden EC, Stark GR. Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol. 2014;41(2):156–173. doi:10.1053/j.seminoncol.2014.02.002.
   PubMed Web of Science ®Google Scholar
• Xiao W, Klement JD, Lu C, Ibrahim ML, Liu K. IFNAR1 controls autocrine type I IFN regulation of PD-L1 expression in myeloid-derived suppressor cells. J Immunol. 2018;201(1):264–277. doi:10.4049/jimmunol.1800129.
   PubMed Web of Science ®Google Scholar
• Shen X, Xu Z, Zhang L, Li J, Wang Y, Li Y, et al. Recent findings in the regulation of programmed death ligand 1 expression. Front Immunol. 2019;10:1337.
   PubMed Web of Science ®Google Scholar
• Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189–1201. doi:10.1016/j.celrep.2017.04.031.
   PubMed Web of Science ®Google Scholar
• Anurag M, Zhu M, Huang C, Vasaikar S, Wang J, Hoog J, Burugu S, Gao D, Suman V, Zhang XH, et al. Immune checkpoint profiles in luminal B breast cancer (Alliance). J Natl Cancer Inst. 2019. doi:10.1093/jnci/djz213.
   Google Scholar
• Ashour J, Laurent-Rolle M, Shi PY, García-Sastre A, et al. NS5 of dengue virus mediates STAT2 binding and degradation. J Virol. 2009;83(11):5408–5418. doi:10.1128/JVI.02188-08.
   PubMed Web of Science ®Google Scholar
• Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JF, Buick R, Stevenson NJ, Touzelet O, Gadina M, et al. Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J Virol. 2007;81(7):3428–3436. doi:10.1128/JVI.02303-06.
   PubMed Web of Science ®Google Scholar
• Grant A, Ponia S, Tripathi S, Balasubramaniam V, Miorin L, Sourisseau M, Schwarz M, Sánchez-Seco M, Evans M, Best S, et al. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe. 2016;19(6):882–890. doi:10.1016/j.chom.2016.05.009.
   PubMed Web of Science ®Google Scholar